Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intratumorally in Patients With Metastatic Renal Cell Carcinoma

Next Previous
X
Search
Trial Profile

A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intratumorally in Patients With Metastatic Renal Cell Carcinoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ilixadencel (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Mendus

    • Most Recent Events

    • 03 Apr 2018 According to an Immunicum media release, has followed the surviving patients over the course of the last 5 years and as of January 18, 2018, which is the final update, three of the 12 patients were still alive.
    • 09 Oct 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 18 Feb 2014 New source identified and integrated: ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top